Other equities research analysts have also recently issued research reports about the company. Deutsche Bank AG increased their price target on DBV Technologies from $46.00 to $56.00 in a research note on Sunday, October 8th. HC Wainwright restated a buy rating and issued a $50.00 price target on shares of DBV Technologies in a research note on Thursday, July 6th. Jefferies Group LLC restated a buy rating on shares of DBV Technologies in a research note on Thursday, August 31st. Zacks Investment Research upgraded DBV Technologies from a hold rating to a buy rating and set a $50.00 price target on the stock in a research note on Tuesday, August 29th. Finally, BidaskClub upgraded DBV Technologies from a hold rating to a buy rating in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $49.63.
DBV Technologies (NASDAQ DBVT) traded up 0.98% during mid-day trading on Tuesday, hitting $23.65. 200,229 shares of the stock were exchanged. The firm has a 50-day moving average price of $41.24 and a 200-day moving average price of $39.09. DBV Technologies has a 12-month low of $21.94 and a 12-month high of $50.57. The stock’s market capitalization is $1.09 billion.
COPYRIGHT VIOLATION WARNING: “DBV Technologies S.A. (DBVT) Upgraded by Societe Generale to “Hold”” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/11/01/dbv-technologies-s-a-dbvt-upgraded-by-societe-generale-to-hold.html.
A number of hedge funds and other institutional investors have recently modified their holdings of DBVT. Parametric Portfolio Associates LLC grew its holdings in DBV Technologies by 9.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 33,270 shares of the company’s stock valued at $1,172,000 after buying an additional 2,794 shares in the last quarter. Morgan Stanley grew its holdings in DBV Technologies by 89.9% in the 1st quarter. Morgan Stanley now owns 249,988 shares of the company’s stock valued at $8,805,000 after buying an additional 118,317 shares in the last quarter. Bank of America Corp DE grew its holdings in DBV Technologies by 86.3% in the 1st quarter. Bank of America Corp DE now owns 26,574 shares of the company’s stock valued at $936,000 after buying an additional 12,309 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in DBV Technologies in the 1st quarter valued at $1,120,000. Finally, Goldman Sachs Group Inc. grew its holdings in DBV Technologies by 3.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 55,499 shares of the company’s stock valued at $1,955,000 after buying an additional 1,647 shares in the last quarter. 45.51% of the stock is currently owned by hedge funds and other institutional investors.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
What are top analysts saying about DBV Technologies S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DBV Technologies S.A. and related companies.